首页> 外文期刊>Rheumatology Advances in Practice >Dramatic improvement of chronic pleural effusion with abatacept treatment in longstanding rheumatoid arthritis, after chest sepsis during treatment with anti-TNF-α
【24h】

Dramatic improvement of chronic pleural effusion with abatacept treatment in longstanding rheumatoid arthritis, after chest sepsis during treatment with anti-TNF-α

机译:长效类风湿性关节炎患者长期接受抗TNF-α治疗后发生脓毒症后,使用abatacept治疗可显着改善慢性胸腔积液

获取原文
           

摘要

Introduction Rheumatoid arthritis (RA) is a systemic inflammatory disorder, with various pulmonary manifestations, including parenchymal disease (interstitial lung disease), inflammation of the pleura (thickening and effusions), and inflammation of the airways and pulmonary vasculature (vasculitis and pulmonary hypertension). These changes may reflect chronic immune activation, increased susceptibility to infection, or direct toxicity from disease modifying or biological therapy. This case report describes a 69-year-old male with longstanding seropositive rheumatoid arthritis who developed severe pneumonia during adalimumab treatment, with subsequent persistent right basal pleural effusion. Treatment with abatacept has resulted in remission with significant decrease in size of the pleural effusion. Case description This patient attended the difficult asthma clinic and also ENT. Nasal polyps, troublesome post-nasal drip and persistent sinus infections led to 2 polypectomies and surgical turbinate resection. Both rheumatoid factor and anti-CCP positive, he was treated with myocrisin, distamine and methotrexate sequentially, without satisfactory response. He was commenced on adalimumab 40mg subcutaneously fortnightly and achieved remission for 22 months. Over a 6-week period he experienced increasing dyspnoea and productive cough. Adalimumab was omitted. Despite three oral antibiotics he continued to deteriorate and developed sepsis (white cell count 13, CRP 277) with an acute kidney injury. Chest radiograph showed right middle lobe infiltrates. CT chest showed no evidence of pulmonary fibrosis or bronchiectasis. Sputum was negative including for atypical infection. Interferon Gamma Release Assay (IGRA) was positive; sputum and urine culture for tuberculosis (TB) were negative after 6 weeks. After the acute episode, repeat contrast CT chest demonstrated residual inflammatory changes in the right lower lobe with a small pleural effusion. Widespread synovitis developed; sulfasalazine was commenced with low dose oral corticosteroids. Interval imaging showed significant increase in effusion. Pleural aspiration confirmed an exudate with a total protein of 77?g/L and an LDH of 2364u/L. Glucose was undetectable and pH low consistent with a cellular metabolically active effusion. No organisms were identified. Thorascopic biopsy revealed fibrinous pleuritis with chronic inflammation, but no evidence of malignancy, ILD, granulomata. Mycobacterial cultures were negative. Over the successive months the patient was managed with sulfasalazine, oral prednisone 5-7.5mg, intra-articular injections and he had a period of relative stability. Joint disease then flared with dramatic synovitis, and a DAS-28 score of 6.46 was documented. Abatacept 125mg subcutaneously weekly was initiated with excellent clinical response. DAS-28 score 2.5 at 6 months, with no infective episodes, and the pleural effusion has significantly reduced in size. Discussion Symptomatic pleural involvement affects 3-5% patients with RA, is more common in older males and those with rheumatoid nodules. Most effusions are unilateral. In this case, effusion persisted after resolution of infection, and the clinical picture was not in keeping with parapneumonic effusion/empyema. Differential aetiologies included rheumatoid, tuberculosis (particularly in the setting of previous anti-TNF) and malignancy. Typically, a rheumatoid effusion is sterile exudate with low pH, low glucose and elevated LDH. Rheumatoid factor may be present. White cell count and cell predominance is variable. Characteristic multinucleated macrophages and necrotic background debris may be seen. Here, the pleural aspiration was not definitive in determining aetiology. Cytology confirmed large numbers of acute inflammatory cells accompanied by macrophages and mesothelial cells. Occasional multinucleated giant cells were seen; these have been described in both tuberculous and rheumatoid effusions. No alcohol/acid fast bacilli were cultured. A sample was sent for adenosine deaminase (ADA). Low ADA excludes tuberculous effusion however it is recognised that in rheumatoid disease it may be elevated. The ADA was elevated at 69?IU/L (0 - 45). If the diagnosis remains unclear, as in this case, histological examination of the pleura may reveal replacement of the normal mesothelial lining with multinucleated giant cells and foci of palisading fibroblasts and lymphocytes surrounding necrotic centres, similar to rheumatoid nodules. This gentleman’s biopsy demonstrated fibrinous pleuritis with chronic inflammation and some patchy mesothelial hyperplasia and no evidence of granulomatous inflammation. The pathologist stated that these appearances are observed in patients with rheumatoid arthritis but are not specific. Most cases of rheumatoid pleuritis improve with treatment of the underlying arthritis; small, asymptomatic effusions don’t require specific intervention. However, persistent effusion can lead to
机译:简介类风湿关节炎(RA)是一种全身性炎症性疾病,具有多种肺部表现,包括实质性疾病(间质性肺疾病),胸膜炎症(增厚和积液)以及气道和肺血管系统的炎症(血管炎和肺动脉高压) 。这些变化可能反映了慢性免疫激活,对感染的敏感性增加或疾病改良或生物疗法的直接毒性。该病例报告描述了一位69岁的男性,患有长期血清反应阳性的类风湿关节炎,在阿达木单抗治疗期间发生了严重的肺炎,并伴有持续的右基底基底膜胸腔积液。阿巴西普治疗已导致症状缓解,胸腔积液大小明显减少。病例描述该患者曾在困难的哮喘门诊和耳鼻喉科就诊。鼻息肉,麻烦的鼻后滴注和持续的鼻窦感染导致2例多视镜和外科鼻甲切除术。类风湿因子和抗CCP均阳性,他先后接受了肌球蛋白,灭明敏和甲氨蝶呤治疗,但没有令人满意的反应。他每两周开始皮下注射40mg阿达木单抗,并缓解了22个月。在6周的时间内,他经历了呼吸困难加重和产生性咳嗽。阿达木单抗被省略。尽管使用了三种口服抗生素,他仍继续恶化并发展为败血症(白细胞计数13,CRP 277),并伴有急性肾损伤。胸部X线片显示右中叶浸润。 CT胸部未显示肺纤维化或支气管扩张的证据。痰为阴性,包括非典型感染。干扰素γ释放测定(IGRA)为阳性; 6周后,痰和尿培养的结核病(TB)阴性。急性发作后,重复的对比CT胸部显示右下叶残留有炎症变化,并伴有少量胸腔积液。广泛性滑膜炎的发展;柳氮磺吡啶开始于低剂量口服糖皮质激素治疗。间隔成像显示积液明显增加。胸膜穿刺证实渗出液的总蛋白为77?g / L,LDH为2364u / L。葡萄糖不可检测,pH低,与细胞代谢活跃积液一致。没有发现生物。胸腔镜活检显示纤维性胸膜炎伴慢性炎症,但无恶性,ILD,肉芽肿迹象。分枝杆菌培养阴性。在连续的几个月中,患者接受柳氮磺胺吡啶,口服泼尼松5-7.5mg,关节内注射治疗,并且有一段相对的稳定期。关节疾病随后发作,并伴有严重的滑膜炎,并且DAS-28评分为6.46。每周皮下注射Abatacept 125mg具有良好的临床反应。 DAS-28在6个月时得分为2.5,无感染发作,并且胸腔积液的大小明显减少。讨论症状性胸膜受累影响3-5%的RA患者,在老年男性和类风湿结节患者中更为常见。大多数积液是单方面的。在这种情况下,在感染消退后仍会继续积液,并且临床表现与肺炎旁肺积液/肺气肿并不一致。鉴别病因包括类风湿,结核病(尤其是先前使用过的抗TNF药物)和恶性肿瘤。通常,类风湿积液是具有低pH,低葡萄糖和升高的LDH的无菌渗出液。可能存在类风湿因子。白细胞计数和细胞优势是可变的。可以看到特征性的多核巨噬细胞和坏死背景碎片。在这里,胸膜穿刺术并不能确定病因。细胞学检查证实大量急性炎症细胞伴有巨噬细胞和间皮细胞。偶尔可见多核巨细胞;这些在结核性和类风湿性积液中都有描述。没有培养耐酒精/耐酸细菌。发送样品用于腺苷脱氨酶(ADA)。低ADA排除了结核性积液,但是人们认识到在类风湿性疾病中它可能会升高。 ADA升高至69?IU / L(0-45)。如果这种情况的诊断尚不清楚,则在这种情况下,对胸膜进行组织学检查可能会发现,正常的间皮内层被多核巨细胞和坏死中心周围呈弥散性成纤维细胞和淋巴细胞的病灶取代,类似于类风湿结节。这位先生的活组织检查显示纤维性胸膜炎伴有慢性炎症和一些间皮增生,没有肉芽肿性炎症的迹象。病理学家指出,这些外观在类风湿关节炎患者中观察到,但不是特异性的。类风湿性胸膜炎的大多数病例可通过治疗潜在的关节炎得到改善。小而无症状的积液不需要特殊干预。但是,持续的积液会导致

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号